David A. Palma, MD, PhD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs Surgery

October 27, 2021 By The ASCO Post Staff

David A. Palma, MD, PhD, of Ontario’s London Health Sciences Centre, discusses results of the ORATOR2 study, which compared two treatment options that could be de-escalated for patients with HPV-associated oropharyngeal squamous cell carcinoma: a lower-dose radiation approach (6 weeks instead of 7, often with chemotherapy) vs a transoral surgical approach (with low-dose radiation afterward, for 5 weeks) (Abstract LBA2).

Related Content